StockData
Perspective Therapeutics, Inc. logo

Perspective Therapeutics, Inc. (CATX) company profile

CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$0.75−0.03 (-3.85%)

Close on Nov 20, 2026Market cap $86.05MP/E –Yield –

About Perspective Therapeutics

Pharmaceutical Preparations, SIC 2834

Perspective Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted alpha therapies and alpha-particle therapeutic drug candidates to treat serious diseases. Its pipeline of investigational drug product candidates includes PSV359, VMT-α-NET, and VMT01, which are undergoing research and clinical evaluation. The company conducts research, clinical development, and finishing operations for its therapeutic assets, supported by subsidiaries including Viewpoint Molecular Targeting, Inc. and Isoray Medical, Inc. Its intended end users and customers encompass patients participating in clinical trials, physicians, healthcare payors, and major treatment centers.

The company maintains its principal executive offices in Seattle, Washington. Perspective Therapeutics conducts its operations domestically within the United States, utilizing facilities in Seattle as well as Coralville, Iowa. Its physical infrastructure includes office space and specialized finishing facilities intended to supply drug candidates to treatment centers across the country.

Summary of the business section of Perspective Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Perspective Therapeutics, Inc.
Headquarters
Seattle, WA
Address
2401 Elliott Avenue, Suite 320 98121
Phone
(206) 676-0900
Employees
166, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
WithumSmith+Brown, PC, San Francisco, CA, USA

Stock & identifiers

Ticker
CATX
Former tickers
ISR until Mar 13, 2023
Exchange
NYSE
Shares outstanding
114M, Aug 5, 2026
Public float
$212.87M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-10 reverse, Jun 17, 2024
SEC CIK
728387
CUSIP
46489V302
ISIN
US46489V3024
FIGI
BBG000BG5HT7
Share class FIGI
BBG001S5Q300
LEI
5493005LRKM6BCABC605
EIN
41-1458152

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Johan M. SpoorChief Executive Officer, Director134,683
Markus PuhlmannChief Medical Officer178,542
Jonathan Robert HuntChief Accounting Officer59,800
Joel SendekChief Financial Officer–
Juan GrahamChief Financial Officer35,354
Robert F. Williamson IIIDirector183,744
Frank MorichDirector30,000
Lori A. WoodsDirector212,017
Maria E. MartinezDirector–
Heidi HensonDirector25,975

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.40M$2.21M$1.76M$110–
FY2024$5.38M$2.19M$1.77M$128–
FY2023
Johan Thijs Spoor
$1.46M$1.82M$1.04M$160–
FY2023
Lori AWoods
$671.73K$776.66K$1.04M$160–
FY2022$550.59K$481.04K$330.89K$31–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payOtherTotalvs. prior year
Johan (Thijs) Spoor
CEO and Director
$680.00K–$1.30M$408.00K$14.00K$2.40M-55%
Joel Sendek
Chief Financial Officer
$163.01K–$1.75M$65.20K$7.50K$1.99M–
Juan Graham
Former Chief Financial Officer
$334.73K$80.00K$1.16M–$660.42K$2.23M–
Markus Puhlmann
Chief Medical Officer
$516.70K–$330.68K$206.70K$14.00K$1.07M-48%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of March 12, 2026, we employed 166 individuals, of which 163 were full-time employees and three were part-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 20, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 16, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 8, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 16, 2023Name changeName changed from Isoray, Inc. to Perspective Therapeutics, Inc.
Feb 6, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 7, 2022Merger voteDefinitive merger proxy statement
Apr 12, 2007ListingRegistration of securities on an exchange (Form 8-A)
May 15, 2006Late filingNotification of late filing
Feb 14, 2006Late filingNotification of late filing
Dec 14, 2005Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 14, 2005Late filingNotification of late filing
Sep 29, 2005Late filingNotification of late filing
Aug 3, 2005Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 3, 2005Name changeName changed from CENTURY PARK PICTURES CORP to IsoRay, Inc.
Aug 14, 1997Late filingNotification of late filing
Dec 24, 1996Late filingNotification of late filing
May 16, 1996Late filingNotification of late filing
Jan 16, 1996Late filingNotification of late filing

See a number that looks wrong?